## Randall C Starling

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2995791/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Importance of Venous Congestion for Worsening of Renal Function in Advanced Decompensated Heart Failure. Journal of the American College of Cardiology, 2009, 53, 589-596.	2.8	1,313
2	Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients. New England Journal of Medicine, 2003, 349, 847-858.	27.0	1,104
3	Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. Journal of Heart and Lung Transplantation, 2010, 29, S1-S39.	0.6	798
4	Unexpected Abrupt Increase in Left Ventricular Assist Device Thrombosis. New England Journal of Medicine, 2014, 370, 33-40.	27.0	743
5	The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease. Circulation, 2007, 116, 2216-2233.	1.6	734
6	Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nature Reviews Cardiology, 2021, 18, 169-193.	13.7	589
7	Controlled Trial of Intravenous Immune Globulin in Recent-Onset Dilated Cardiomyopathy. Circulation, 2001, 103, 2254-2259.	1.6	515
8	Results of the Post-U.S. Food and Drug Administration-Approval Study With a Continuous Flow Left Ventricular Assist Device as a Bridge to Heart Transplantation. Journal of the American College of Cardiology, 2011, 57, 1890-1898.	2.8	434
9	Insights From a Cardiac Resynchronization Optimization Clinic as Part of a Heart Failure Disease Management Program. Journal of the American College of Cardiology, 2009, 53, 765-773.	2.8	424
10	An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. Journal of Heart and Lung Transplantation, 2014, 33, 23-34.	0.6	421
11	Cardiac Improvement During Mechanical Circulatory Support. Circulation, 2007, 115, 2497-2505.	1.6	376
12	The role of endomyocardial biopsy in the management of cardiovascular disease: A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology, European Heart Journal, 2007, 28, 3076-3093	2.2	336
13	Risk Assessment and Comparative Effectiveness of Left Ventricular AssistÂDevice and Medical Management inÂAmbulatory Heart Failure Patients. Journal of the American College of Cardiology, 2015, 66, 1747-1761.	2.8	311
14	Vagus Nerve Stimulation for the Treatment of Heart Failure. Journal of the American College of Cardiology, 2016, 68, 149-158.	2.8	283
15	Early results with partial left ventriculectomy. Journal of Thoracic and Cardiovascular Surgery, 1997, 114, 755-765.	0.8	231
16	Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: Results of the adaptive CRT trial. Heart Rhythm, 2012, 9, 1807-1814.e1.	0.7	223
17	Clinical and Demographic Predictors of Outcomes in Recent Onset Dilated Cardiomyopathy. Journal of the American College of Cardiology, 2011, 58, 1112-1118.	2.8	202
18	Are All Readmissions Bad Readmissions?. New England Journal of Medicine, 2010, 363, 297-298.	27.0	195

#	Article	IF	CITATIONS
19	The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal, 2019, 40, 2155-2163.	2.2	195
20	Sodium Nitroprusside for Advanced Low-Output Heart Failure. Journal of the American College of Cardiology, 2008, 52, 200-207.	2.8	184
21	Reframing the association and significance of coâ€morbidities in heart failure. European Journal of Heart Failure, 2016, 18, 744-758.	7.1	169
22	The HVAD Left Ventricular Assist Device. JACC: Heart Failure, 2015, 3, 818-828.	4.1	167
23	Heart Failure and Liver Disease. JACC: Heart Failure, 2019, 7, 87-97.	4.1	162
24	Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients. JACC: Heart Failure, 2017, 5, 518-527.	4.1	159
25	Heart failure and COVID-19. Heart Failure Reviews, 2021, 26, 1-10.	3.9	152
26	Virtual Visits for Care of Patients with Heart Failure in the Era of COVID-19: A Statement from the Heart Failure Society of America. Journal of Cardiac Failure, 2020, 26, 448-456.	1.7	146
27	Risk factors, mortality, and timing of ischemic and hemorrhagic stroke with left ventricular assist devices. Journal of Heart and Lung Transplantation, 2017, 36, 673-683.	0.6	142
28	Clinical outcomes with synchronized left ventricular pacing: Analysis of the adaptive CRT trial. Heart Rhythm, 2013, 10, 1368-1374.	0.7	139
29	Partial left ventriculectomy for dilated cardiomyopathy: Is this an alternative to transplantation?. Journal of Thoracic and Cardiovascular Surgery, 2001, 121, 879-893.	0.8	138
30	Clinical Evaluation of the CorCap Cardiac Support Device in Patients With Dilated Cardiomyopathy. Annals of Thoracic Surgery, 2007, 84, 1226-1235.	1.3	128
31	Prognosis on Chronic Dobutamine or Milrinone Infusions for Stage D Heart Failure. Circulation: Heart Failure, 2009, 2, 320-324.	3.9	128
32	Prognostic Role of Serum Chloride Levels in Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2015, 66, 659-666.	2.8	123
33	Partial left ventriculectomy and mitral valve repair for end-stage congestive heart failure1. European Journal of Cardio-thoracic Surgery, 1998, 13, 337-343.	1.4	120
34	Molecular Testing in the Management of Cardiac Transplant Recipients: Initial Clinical Experience. Journal of Heart and Lung Transplantation, 2006, 25, 1389-1395.	0.6	114
35	The management of antibodies in heart transplantation: An ISHLT consensus document. Journal of Heart and Lung Transplantation, 2018, 37, 537-547.	0.6	114
36	Usefulness of Neutrophil-to-Lymphocyte Ratio in Risk Stratification of Patients With Advanced Heart Failure. American Journal of Cardiology, 2015, 115, 57-61.	1.6	111

#	Article	IF	CITATIONS
37	Cardiac Allograft Vasculopathy by Intravascular Ultrasound in HeartÂTransplantÂPatients. JACC: Heart Failure, 2013, 1, 389-399.	4.1	110
38	Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]). Circulation, 2020, 142, 2016-2028.	1.6	108
39	Sustained Benefits of the CorCap Cardiac Support Device on Left Ventricular Remodeling: Three Year Follow-up Results From the Acorn Clinical Trial. Annals of Thoracic Surgery, 2007, 84, 1236-1242.	1.3	105
40	Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?. Circulation: Heart Failure, 2013, 6, 727-732.	3.9	103
41	Updated definitions of adverse events for trials and registries of mechanical circulatory support: A consensus statement of the mechanical circulatory support academic research consortium. Journal of Heart and Lung Transplantation, 2020, 39, 735-750.	0.6	101
42	Continuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical Trial. Annals of Thoracic Surgery, 2011, 92, 1406-1413.	1.3	97
43	Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial. International Journal of Cardiology, 2014, 172, 115-121.	1.7	96
44	Management of the Waiting List for Cadaveric Kidney Transplants. Journal of the American Society of Nephrology: JASN, 2002, 13, 528-535.	6.1	95
45	Mitral valve repair in heart failure: Five-year follow-up from the mitral valve replacement stratum of the Acorn randomized trial. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 569-574.e1.	0.8	87
46	Beneficial effects of the CorCap cardiac support device: Five-year results from the Acorn Trial. Journal of Thoracic and Cardiovascular Surgery, 2012, 143, 1036-1042.	0.8	85
47	Unplanned Hospital Readmissions After HeartMate II Implantation. JACC: Heart Failure, 2013, 1, 31-39.	4.1	84
48	Body Weight Change During and AfterÂHospitalization for Acute HeartÂFailure:ÂPatient Characteristics, Markers of Congestion, and Outcomes. JACC: Heart Failure, 2017, 5, 1-13.	4.1	84
49	Outcome ofDe Novohepatitis C virus infection in heart transplant recipients. Hepatology, 1999, 30, 1293-1298.	7.3	79
50	Does pulsatility matter in the era of continuous-flow blood pumps?. Journal of Heart and Lung Transplantation, 2015, 34, 999-1004.	0.6	78
51	Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 2022, 7, 17.	6.1	77
52	Therapeutic Drug Monitoring for Everolimus in Heart Transplant Recipients Based on Exposure-Effect Modeling. American Journal of Transplantation, 2004, 4, 2126-2131.	4.7	73
53	Outcomes of Patients With Peripartum Cardiomyopathy Who Received Mechanical Circulatory Support. Circulation: Heart Failure, 2014, 7, 300-309.	3.9	70
54	Left ventricular assist devices versus medical management in ambulatory heart failure patients: An analysis of INTERMACS Profiles 4 and 5 to 7 from the ROADMAP study. Journal of Heart and Lung Transplantation, 2018, 37, 706-714.	0.6	68

4

#	Article	IF	CITATIONS
55	Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. Journal of the American College of Cardiology, 2002, 39, 970-977.	2.8	67
56	Persistent Hemodynamic Benefits of Cardiac Resynchronization Therapy With Disease Progression in Advanced Heart Failure. Journal of the American College of Cardiology, 2009, 53, 600-607.	2.8	65
57	Persistent abnormal left ventricular systolic torsion in dilated cardiomyopathy after partial left ventriculectomy. Journal of Thoracic and Cardiovascular Surgery, 2003, 126, 48-55.	0.8	63
58	Results of partial left ventriculectomy for dilated cardiomyopathy. Journal of the American College of Cardiology, 2000, 36, 2098-2103.	2.8	62
59	Major Bleeding During HeartMate II Support. Journal of the American College of Cardiology, 2013, 62, 2188-2196.	2.8	62
60	Cellular rejection and rate of progression of transplant vasculopathy: a 3-year serial intravascular ultrasound study. Journal of Heart and Lung Transplantation, 2001, 20, 393-398.	0.6	58
61	A review of dyspnea in acute heart failure syndromes. American Heart Journal, 2010, 160, 209-214.	2.7	58
62	Current risks of HeartMate II pump thrombosis: Non-parametric analysis of Interagency Registry for Mechanically Assisted Circulatory Support data. Journal of Heart and Lung Transplantation, 2015, 34, 1527-1534.	0.6	56
63	Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York health association class III-IV heart failure. Journal of Cardiac Failure, 2004, 10, 185-192.	1.7	55
64	A novel algorithm for individualized cardiac resynchronization therapy: Rationale and design of the adaptive cardiac resynchronization therapy trial. American Heart Journal, 2012, 163, 747-752.e1.	2.7	54
65	Cerebrovascular Events in Patients With Centrifugal-Flow Left Ventricular Assist Devices: Propensity Score–Matched Analysis From the Intermacs Registry. Circulation, 2021, 144, 763-772.	1.6	54
66	Worldwide clinical experience with the CorCapâ,,¢ Cardiac Support Device. Journal of Cardiac Failure, 2004, 10, S225-S233.	1.7	49
67	Does Survival on the Heart Transplant Waiting List Depend on the Underlying Heart Disease?. JACC: Heart Failure, 2016, 4, 689-697.	4.1	49
68	Long-Term Mortality After Cardiac Allograft Vasculopathy. JACC: Heart Failure, 2014, 2, 281-288.	4.1	48
69	Impact of a Novel Adaptive Optimization Algorithm on 30-Day Readmissions. JACC: Heart Failure, 2015, 3, 565-572.	4.1	48
70	What Causes LVAD-Associated Ischemic Stroke? Surgery, Pump Thrombosis, Antithrombotics, and Infection. ASAIO Journal, 2019, 65, 775-780.	1.6	47
71	Outcomes of Heart Transplant After Left Ventricular Assist Device Specific and RelatedÂInfection. Annals of Thoracic Surgery, 2015, 100, 1292-1297.	1.3	46
72	Destination Therapy With Left Ventricular Assist Devices: For Whom and When?. Canadian Journal of Cardiology, 2014, 30, 296-303.	1.7	45

#	Article	IF	CITATIONS
73	Preload Sensitivity in Cardiac Assist Devices. Annals of Thoracic Surgery, 2013, 95, 373-380.	1.3	44
74	Frequency of Depression and Anxiety Before and After Insertion of a Continuous Flow Left Ventricular Assist Device. American Journal of Cardiology, 2014, 114, 433-440.	1.6	44
75	A disproportionate elevation in right ventricular filling pressure, in relation to left ventricular filling pressure, is associated with renal impairment and increased mortality in advanced decompensated heart failure. American Heart Journal, 2015, 169, 806-812.	2.7	44
76	Implications of Serum Chloride Homeostasis in Acute Heart Failure (from ROSE-AHF). American Journal of Cardiology, 2017, 119, 78-83.	1.6	44
77	The impact of left ventricular reconstruction on survival in patients with ischemic cardiomyopathy. European Journal of Cardio-thoracic Surgery, 2006, 30, 753-759.	1.4	43
78	Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality. Circulation: Heart Failure, 2014, 7, 918-925.	3.9	42
79	Patient-Reported Health-Related Quality of Life Is a Predictor of Outcomes in Ambulatory Heart Failure Patients Treated With Left Ventricular Assist Device Compared With Medical Management. Circulation: Heart Failure, 2017, 10, .	3.9	42
80	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCENDâ€HF. European Journal of Heart Failure, 2018, 20, 304-314.	7.1	42
81	The Enemy Within. Circulation, 2020, 142, 1865-1870.	1.6	42
82	Myocardial Ischemic Injury After Heart Transplantation Is Associated With Upregulation of Vitronectin Receptor ( $l_{\pm} v l^2 3$ ), Activation of the Matrix Metalloproteinase Induction System, and Subsequent Development of Coronary Vasculopathy. Circulation, 2002, 105, 1955-1961.	1.6	41
83	Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure. Circulation, 2014, 130, 958-965.	1.6	41
84	Predictors of early dyspnoea relief in acute heart failure and the association with 30â€day outcomes: findings from ASCENDâ€HF. European Journal of Heart Failure, 2013, 15, 456-464.	7.1	39
85	Limitations to Chronic Right Ventricular Assist Device Support. Annals of Thoracic Surgery, 2016, 102, 651-658.	1.3	39
86	Sacubitril/Valsartan in Advanced HeartÂFailure With Reduced Ejection Fraction. JACC: Heart Failure, 2020, 8, 789-799.	4.1	39
87	Residual high incidence of ventricular arrhythmias after left ventricular reconstructive surgery. Journal of Thoracic and Cardiovascular Surgery, 2005, 130, 1250-1256.	0.8	38
88	Increase in Left Ventricular Assist Device Thrombosis. New England Journal of Medicine, 2014, 370, 1463-1466.	27.0	38
89	Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation. Journal of the American College of Cardiology, 2019, 74, 36-51.	2.8	37
90	Prognostic role of cardiac power index in ambulatory patients with advanced heart failure. European Journal of Heart Failure, 2015, 17, 689-696.	7.1	35

#	Article	IF	CITATIONS
91	Implantable Continuous-Flow Right Ventricular Assist Device: Lessons Learned in the Development of a Cleveland Clinic Device. Annals of Thoracic Surgery, 2012, 93, 1746-1752.	1.3	34
92	Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: Design and rationale of the ROADMAP clinical trial. American Heart Journal, 2015, 169, 205-210.e20.	2.7	32
93	Does the UNOS Heart Transplant Allocation System Favor Men Over Women?. JACC: Heart Failure, 2014, 2, 347-355.	4.1	31
94	Inotropic Therapy for End-Stage Heart Failure Patients. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 409-419.	0.9	30
95	Standardized Psychosocial Assessment Before Left Ventricular Assist Device Implantation. Circulation: Heart Failure, 2019, 12, e005377.	3.9	30
96	Accuracy of Seattle Heart Failure Model and HeartMate II Risk Score in Non–Inotrope-Dependent Advanced Heart Failure Patients. Circulation: Heart Failure, 2017, 10, .	3.9	29
97	Heart failure with preserved ejection fraction: Classification based upon phenotype is essential for diagnosis and treatment. Trends in Cardiovascular Medicine, 2018, 28, 392-400.	4.9	29
98	The Impact of Infection and Elevated INR in LVAD-Associated Intracranial Hemorrhage: A Case-Crossover Study. ASAIO Journal, 2019, 65, 545-549.	1.6	29
99	Endpoints in HeartÂFailure DrugÂDevelopment. JACC: Heart Failure, 2020, 8, 429-440.	4.1	28
100	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq0	0 0 rgBT /	Overlock 10 Tf
101	Discovery of non-HLA antibodies associated with cardiac allograft rejection and development and validation of a non-HLA antigen multiplex panel: From bench to bedside. American Journal of Transplantation, 2020, 20, 2768-2780.	4.7	26
102	A unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. PLoS ONE, 2017, 12, e0170456.	2.5	26
103	The role of vitronectin receptor (αvβ3) and tissue factor in the pathogenesis of transplant coronary vasculopathy. Journal of the American College of Cardiology, 2002, 39, 804-810.	2.8	25
104	Implantable Cardiac Defibrillators and Sudden Death in Recent Onset Nonischemic Cardiomyopathy: Results From IMAC2. Journal of Cardiac Failure, 2012, 18, 675-681.	1.7	25
105	Contemporary outcomes of outpatients referred for cardiac transplantation evaluation to a tertiary heart failure center: impact of surgical alternatives. Journal of Cardiac Failure, 2004, 10, 273-278.	1.7	24
106	The Impact of Hypogammaglobulinemia on Infection Outcome in Patients Undergoing Ventricular Assist Device Implantation. Journal of Heart and Lung Transplantation, 2006, 25, 820-824.	0.6	24
107	Percutaneous Lead Dysfunction in the HeartMate II Left Ventricular Assist Device. Annals of Thoracic Surgery, 2014, 97, 1373-1378.	1.3	24
108	Continuously Updated Estimation of Heart Transplant Waitlist Mortality. Journal of the American College of Cardiology, 2018, 72, 650-659.	2.8	24

#	Article	IF	CITATIONS
109	Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation. Journal of the American Heart Association, 2020, 9, e015897.	3.7	24
110	Left atrial assist device to treat patients with heart failure with preserved ejection fraction: Initial inÂvitro study. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 120-126.	0.8	23
111	Differences in Treatment, Outcomes, and Quality of Life Among Patients With Heart Failure in Canada and the United States. JACC: Heart Failure, 2013, 1, 523-530.	4.1	22
112	Insufficient reduction in heart rate during hospitalization despite betaâ€blocker treatment in acute decompensated heart failure: insights from the ASCENDâ€HF trial. European Journal of Heart Failure, 2017, 19, 241-249.	7.1	22
113	Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCENDâ€HF. Clinical Cardiology, 2018, 41, 945-952.	1.8	22
114	Ischemic Stroke and Intracranial Hemorrhages During Impella Cardiac Support. ASAIO Journal, 2020, 66, e105-e109.	1.6	22
115	Computerized scoring of histopathology for predicting coronary vasculopathy, validated by intravascular ultrasound. Journal of Heart and Lung Transplantation, 2002, 21, 850-859.	0.6	21
116	Duration of Heart Failure Is an Important Predictor of Outcomes After Mechanical Circulatory Support. Circulation: Heart Failure, 2015, 8, 953-959.	3.9	21
117	Optimal Timing of Heart Transplant After HeartMate II Left Ventricular Assist Device Implantation. Annals of Thoracic Surgery, 2017, 104, 1569-1576.	1.3	21
118	Prospective assessment of combined handgrip strength and Miniâ€Cog identifies hospitalized heart failure patients at increased postâ€hospitalization risk. ESC Heart Failure, 2018, 5, 948-952.	3.1	21
119	Transient Hyponatremia During Hospitalization for Acute Heart Failure. American Journal of Medicine, 2016, 129, 620-627.	1.5	19
120	Left Ventricular Assist Devices: From the Bench to the Clinic. Cardiology, 2013, 125, 1-12.	1.4	18
121	Adaptive CRT in patients with normal AV conduction and left bundle branch block: Does QRS duration matter?. International Journal of Cardiology, 2017, 240, 297-301.	1.7	18
122	Prognostic Utility of Right Ventricular Free Wall Strain in Low Risk Patients After Orthotopic Heart Transplantation. American Journal of Cardiology, 2017, 119, 1890-1896.	1.6	18
123	Noninvasive assessment of cardiac mechanics and clinical outcome after partial left ventriculectomy. Annals of Thoracic Surgery, 2003, 76, 1576-1585.	1.3	17
124	Minimally invasive biventricular mechanical circulatory support with Impella pumps as a bridge to heart transplantation: a firstâ€inâ€theâ€world case report. ESC Heart Failure, 2019, 6, 552-554.	3.1	17
125	The Counter Regulatory Axis of the Lung Renin-Angiotensin System in Severe COVID-19: Pathophysiology and Clinical Implications. Heart Lung and Circulation, 2021, 30, 786-794.	0.4	16
126	Device-based treatment options for heart failure with preserved ejection fraction. Heart Failure Reviews, 2021, 26, 749-762.	3.9	16

#	Article	IF	CITATIONS
127	Partial left ventriculectomy: sunrise or sunset?. European Journal of Heart Failure, 1999, 1, 313-317.	7.1	15
128	Coagulopathy in Mechanical Circulatory Support: A Fine Balance. Current Cardiology Reports, 2015, 17, 114.	2.9	15
129	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. Circulation: Heart Failure, 2016, 9, .	3.9	15
130	Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure. Heart Failure Reviews, 2022, 27, 1991-2003.	3.9	15
131	InÂvitro hemodynamic characterization of HeartMate II at 6000 rpm: Implications for weaning and recovery. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 343-348.	0.8	14
132	Inâ€hospital red blood cell distribution width change in patients with heart failure. European Journal of Heart Failure, 2019, 21, 1659-1661.	7.1	14
133	ACE2, the Counter-Regulatory Renin–Angiotensin System Axis and COVID-19 Severity. Journal of Clinical Medicine, 2021, 10, 3885.	2.4	14
134	Atrial Tachyarrhythmias Among Patients With Left Ventricular Assist Devices. JACC: Clinical Electrophysiology, 2019, 5, 459-466.	3.2	13
135	Patients Not Meeting PARADIGM-HF Enrollment Criteria Are Eligible for Sacubitril/Valsartan on the Basis of FDAÂApproval. JACC: Heart Failure, 2017, 5, 460-463.	4.1	12
136	Hemodynamic factors associated with serum chloride in ambulatory patients with advanced heart failure. International Journal of Cardiology, 2018, 252, 112-116.	1.7	12
137	Dynamic prediction of left ventricular assist device pump thrombosis based on lactate dehydrogenase trends. ESC Heart Failure, 2019, 6, 1005-1014.	3.1	12
138	Acute Hemodynamic Effects of Sacubitril-Valsartan In Heart Failure Patients Receiving Intravenous Vasodilator and Inotropic Therapy. Journal of Cardiac Failure, 2021, 27, 368-372.	1.7	12
139	Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF). BMJ Open, 2016, 6, e010201.	1.9	11
140	Tolvaptan in Acute Heart Failure. Journal of the American College of Cardiology, 2017, 69, 1407-1408.	2.8	11
141	Larissa Heart Failure Risk Score: a proposed simple score for risk stratification in chronic heart failure. European Journal of Heart Failure, 2018, 20, 614-616.	7.1	11
142	The Contribution to Hemodynamics Even at Very Low Pump Speeds in the HVAD. Annals of Thoracic Surgery, 2016, 101, 2260-2264.	1.3	10
143	Recovery of Serum Cholesterol Predicts Survival After Left Ventricular Assist Device Implantation. Circulation: Heart Failure, 2016, 9, .	3.9	10
144	Discordance between 'actual' and 'scheduled' check-in times at a heart failure clinic. PLoS ONE, 2017, 12, e0187849.	2.5	10

#	Article	IF	CITATIONS
145	Utility of the Psychosocial Assessment of Candidates for Transplantation in Patients Undergoing Continuous-Flow Left Ventricular Assist Device Implantation. Progress in Transplantation, 2018, 28, 220-225.	0.7	10
146	Treating symptoms and reversing remodelling: clinical and echocardiographic <scp>1â€year</scp> outcomes with percutaneous mitral annuloplasty for mild to moderate secondary mitral regurgitation. European Journal of Heart Failure, 2021, 23, 1971-1978.	7.1	10
147	Advanced heart failure: Transplantation, LVADs, and beyond. Cleveland Clinic Journal of Medicine, 2013, 80, 33-40.	1.3	10
148	S100A1 in Human Heart Failure. Circulation: Heart Failure, 2014, 7, 612-618.	3.9	9
149	Renal Failure Requiring Dialysis Complicating Slow Continuous Ultrafiltration in Acute Heart Failure: Importance of Systolic Perfusion Pressure. Journal of Cardiac Failure, 2015, 21, 108-115.	1.7	9
150	Initiation of Angiotensin Receptor-Neprilysin Inhibitor in HeartÂFailure With Low Cardiac Output. Journal of the American College of Cardiology, 2019, 74, 2326-2327.	2.8	9
151	Large animal models of heart failure with preserved ejection fraction. Heart Failure Reviews, 2022, 27, 595-608.	3.9	9
152	Postimplant Phosphodiesterase-5 Inhibitor Use in Centrifugal Flow LeftÂVentricular Assist Devices. JACC: Heart Failure, 2022, 10, 89-100.	4.1	9
153	Obesity, inflammation, and heart failure: links and misconceptions. Heart Failure Reviews, 2021, , 1.	3.9	8
154	Left atrial assist device for heart failure with preserved ejection fraction: initial results with torque control mode in diastolic heart failure model. Heart Failure Reviews, 2021, , 1.	3.9	8
155	A case series of cardiac amyloidosis patients supported by continuousâ€flow left ventricular assist device. ESC Heart Failure, 2021, 8, 4353-4356.	3.1	7
156	Medical Treatment of Heart Failure: Ignore the Ejection Fraction and Treat All?. Journal of Cardiac Failure, 2021, 27, 907-909.	1.7	7
157	Cerebral Microvascular Injury in Patients with Left Ventricular Assist Device: a Neuropathological Study. Translational Stroke Research, 2022, 13, 257-264.	4.2	7
158	Care for patients with ventricular assist devices and suspected <scp>COVID</scp> â€19 infection. European Journal of Heart Failure, 2020, 22, 937-940.	7.1	7
159	The Effects of Preserving Mitral Valve Function on a Left Atrial Assist Device: An In Vitro Mock Circulation Loop Study. ASAIO Journal, 2021, 67, 567-572.	1.6	7
160	Introduction: Cardiac Surgery for Heart Failure. Seminars in Thoracic and Cardiovascular Surgery, 2002, 14, 122-124.	0.6	6
161	Surgical remodeling in ischemic cardiomyopathy. Current Treatment Options in Cardiovascular Medicine, 2003, 5, 311-319.	0.9	6
162	Response and tolerance to oral vasodilator upâ€ŧitration after intravenous vasodilator therapy in advanced decompensated heart failure. European Journal of Heart Failure, 2015, 17, 956-963.	7.1	6

#	Article	IF	CITATIONS
163	Cardiac Myosin Activators for the Treatment of Heart Failure. Journal of the American College of Cardiology, 2016, 67, 1456-1458.	2.8	6
164	<scp>Sacubitril/valsartan</scp> in patients <scp>postâ€left</scp> ventricular assist device implant: a <scp>singleâ€centre</scp> case series. European Journal of Heart Failure, 2020, 22, 1490-1492.	7.1	6
165	Chronic Heart Failure: Diagnosis and Management beyond LVEF Classification. Journal of Clinical Medicine, 2022, 11, 1718.	2.4	6
166	Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure. American Heart Journal, 2017, 183, 35-39.	2.7	5
167	Clinical Courses of HeartMate II Left Ventricular Assist Device Thrombosis. ASAIO Journal, 2020, 66, 153-159.	1.6	5
168	Left atrial assist device function at various heart rates using a mock circulation loop. International Journal of Artificial Organs, 2021, 44, 465-470.	1.4	5
169	Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure. Journal of Cardiac Failure, 2022, 28, 916-923.	1.7	5
170	Incremental Value of Global Longitudinal Strain to Michigan Risk Score and Pulmonary Artery Pulsatility Index in Predicting Right Ventricular Failure Following Left Ventricular Assist Devices. Heart Lung and Circulation, 2022, 31, 1110-1118.	0.4	5
171	Comparison of Left Ventricular Torsion and Strain With Biventricular Pacing in Patients With Underlying Right Bundle Branch Block Versus Those With Left Bundle Branch Block. American Journal of Cardiology, 2015, 115, 918-923.	1.6	4
172	Left ventricular assist device thrombosis in the setting of left ventricular recovery. Journal of Heart and Lung Transplantation, 2015, 34, 622-623.	0.6	4
173	Cerebral Microembolization in Left Ventricular Assist Device Associated Ischemic Events. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104660.	1.6	4
174	Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. Journal of Cardiac Failure, 2021, 27, 297-308.	1.7	4
175	Kinetics of generic tacrolimus in heart transplantation: A cautionary note. Journal of Heart and Lung Transplantation, 2021, 40, 569-572.	0.6	4
176	Left Atrial Circulatory Assistance in Simulated Diastolic Heart Failure Model: First in Vitro and in Vivo. Journal of Cardiac Failure, 2022, , .	1.7	4
177	Post-acute Care Trajectories in the First Year Following Hospital Discharge After Left Ventricular Assist Device Implantation. Journal of the American Medical Directors Association, 2016, 17, 908-912.	2.5	3
178	The axial continuous-flow blood pump: Bench evaluation of changes in flow associated with changes of inflow cannula angle. Journal of Heart and Lung Transplantation, 2017, 36, 106-112.	0.6	3
179	Impact of an electronic medical record-based appointment order on outpatient cardiology follow-up after hospital discharge. Npj Digital Medicine, 2021, 4, 77.	10.9	3
180	Cardiac resynchronisation therapy in anthracycline-induced cardiomyopathy. Heart, 2021, , heartjnl-2020-318333.	2.9	3

#	Article	IF	CITATIONS
181	Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. American Heart Journal, 2021, 239, 110-119.	2.7	3
182	Less invasive versus conventional heart valve surgery in patients withÂsevere heart failure. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 161-167.e6.	0.8	2
183	Are Outcomes Related to Left Ventricular Assist Device Center Volume?. JACC: Heart Failure, 2017, 5, 700-702.	4.1	2
184	Improving care of chronic heart failure: advances from drugs to devices Cleveland Clinic Journal of Medicine, 2003, 70, 141-146.	1.3	2
185	The Emergence of the HF and Critical Care Medicine Specialist: An Unmet Need That Needs a Rapid Solution. Journal of Cardiac Failure, 2021, , .	1.7	2
186	Left Ventricular Assist Devices Ramp Studies. JACC: Heart Failure, 2015, 3, 300-302.	4.1	1
187	Stable coronary artery disease and left ventricular dysfunction: The role of revascularization. Catheterization and Cardiovascular Interventions, 2017, 90, 777-783.	1.7	1
188	Large animal models to test mechanical circulatory support devices. Drug Discovery Today: Disease Models, 2017, 24, 47-53.	1.2	1
189	Mitral Valve Stenosis: Still a Clinical Challenge?. Cardiology, 2018, 140, 45-46.	1.4	1
190	Obesity Predicts Survival After Cardiac Resynchronization Therapy Independent of Effect on Left Ventricular Ejection Fraction. Circulation: Heart Failure, 2020, 13, e007424.	3.9	1
191	Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). American Journal of Cardiology, 2021, 154, 123-126.	1.6	1
192	Potential Population for Long-Term Use of Left Ventricular Assist Devices. , 2012, , 11-21.		1
193	Reply to â€~Benefits of transvenous mitral annuloplasty in heart failure with lower degrees of functional mitral regurgitation'. European Journal of Heart Failure, 2021, 23, 1985-1986.	7.1	1
194	Patient Population and Selection Criteria for Mechanical Circulatory Support. , 2020, , 131-139.		1
195	Contemporary Trends of Clinical Outcomes in Primary Left Ventricular Assist Device Implantation and Postprocedure High-Risk Categories. Journal of Cardiac Failure, 2022, 28, 270-282.	1.7	1
196	Therapeutic Drug Monitoring for Everolimus in Heart Transplant Recipients: Flawed Model or a Model for Forter f for Future Use?. American Journal of Transplantation, 2005, 5, 2330-2330.	4.7	0
197	Surgical Treatment of Chronic Heart Failure. , 2011, , 802-817.		0
198	Augmenting outcomes in advanced heart failure: a lot to learn. European Journal of Heart Failure, 2016, 18, 326-327.	7.1	0

#	Article	IF	CITATIONS
199	Candidate Selection and Decision Making in Mechanical Circulatory Support. , 2020, , 31-39.		0
200	Stage D Heart Failure With Preserved Ejection Fraction, Heart Transplantation, and Mechanical Circulatory Support. , 2021, , 276-289.		0
201	Needing to vent: best to pitch the vent before heart transplant. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 852-854.	1.0	Ο
202	Does Anyone Read Heart Failure Guidelines? Why You Should Read the Japanese Guideline!. Journal of Cardiac Failure, 2021, 27, 1445-1446.	1.7	0
203	Sacubitril-valsartan and the evolution of heart failure care. Cleveland Clinic Journal of Medicine, 2015, 82, 702-704.	1.3	0
204	Abstract 18412: Lactate Dehydrogenase Trends Predict Left Ventricular Assist Device Thrombosis. Circulation, 2015, 132, .	1.6	0
205	Abstract 17304: Sudden Cardiac Death After Acute Heart Failure Hospitalization: Insights From ASCEND-HF. Circulation, 2015, 132, .	1.6	0
206	Abstract 17888: A Dynamically Updated Cardiac Transplant Waitlist Mortality Score. Circulation, 2015, 132, .	1.6	0
207	Cardiorenal Syndrome in a Patient with Mechanical Circulatory Support. , 2020, , 227-247.		0
208	Incidence and Prognostic Implications of Readmissions Caused by Thrombotic Events After a Heart Failure Hospitalization. Journal of the American Heart Association, 2022, 11, e025342.	3.7	0
209	Abstract 18407: Identifying Patients With Acute Heart Failure who Require a Critical Care Admission: ASCEND-HF Insights. Circulation, 2015, 132, .	1.6	0
210	Abstract 21098: Variables From the CMS Heart Failure Readmission Model Poorly Predict 30-Day Rehospitalization Risk in Heart Failure Patients From a Large Academic Hospital System. Circulation, 2017, 136, .	1.6	0
211	Demand for Mechanical Circulatory Support. , 2022, , 63-77.		0
212	Reduction of Adverse Events With Phosphodiesterase 5 Inhibitors Post LVAD Implantation: Is It Time for a Randomized Trial?. Journal of Cardiac Failure, 2022, , .	1.7	0